Reolysin: Phase I started

Oncolytics began a dose-escalation, U.S. Phase I trial (REO 022) to evaluate 3 dose levels of Relyosin in combination with FOLFIRI (irinotecan, 5-FU and leucovorin) in oxaliplatin-refractory or intole...